SAGE Therapeutics (SAGE) Misses Q2 EPS by 6c; Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Sage Therapeutics Announces Second Quarter 2016 Financial Results and Provides Corporate Update
August 9, 2016 6:30 AM EDTPortfolio Expansion Underway Based on Recent Positive Data from SAGE-547 and SAGE-217
Top-line Data Readout of Phase 3 STATUS Trial in SRSE Now Expected in 1H 2017
Dosing Commenced in Expanded Phase 2 Program for SAGE-547 in Moderate and Severe Postpartum Depression
Phase 2 Initiations Planned for SAGE-217 in Essential Tremor and Postpartum Depression in 2H 2016
Proof-of-Concept Study Initiations Planned with SAGE-547 in Major Depressive Disorder and SAGE-217 in Parkinsons Disease in 2H 2016
Conference Call Today at 8:00 AM ET
... More